Vicor Corporation (VICR) Jumps 5.7% on February 22

Equities Staff |

Vicor Corporation (VICR) was among the biggest gainers on the Russell 2000 for Monday February 22 as the stock popped 5.7% to $7.60, representing a gain of $0.41 per share. Some 66,320 shares traded hands on 384 trades, compared with an average daily volume of 38,375 shares out of a total float of 38.79 million. The stock opened at $7.25 and traded with an intraday range of $7.77 to $7.13.

After today's gains, Vicor Corporation reached a market cap of $294.82 million. Vicor Corporation has had a trading range between $17.72 and $7.00 over the last year, and it had a 50-day SMA of $8.35 and a 200-day SMA of $10.39.

The stock has a P/E Ratio of 42.3.

Vicor Corp is engaged in designing, developing, manufacturing and marketing of modular components and complete systems including power converters, power system components, and power systems for converting, regulating, and controlling electric current.

Vicor Corporation is based out of Andover, MA and has some 1,014 employees. Its CEO is Patrizio Vinciarelli.

For a complete fundamental analysis analysis of Vicor Corporation, check out Equities.com’s Stock Valuation Analysis report for VICR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Lyft

Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…

Cloudera

Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…